Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

Henan Cancer Hospital: Clinical Trials & FDA Approval Profile

Henan Cancer Hospital (Global / Institutional) sponsors 129 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 67 active protocols (38 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)4.7%
Median Closed Enrollment vs National (145 pts)55 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Henan Cancer Hospital
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)129
Active Pipeline (Recruiting Now)67 (38)
Completed vs Stopped Early10 / 6 (4.7%)
Median Closed Actual Enrollment55 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Henan Cancer Hospital
Hospital Research SiteLocationShared Protocols
Henan Cancer HospitalZhengzhou, Henan68

Explore interactive annual charts and M&A subsidiary rollups in the Henan Cancer Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI